Blog
About

1
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      A Trial of Calcitonin Therapy in Renal Osteodystrophy

      , , ,

      Nephron

      S. Karger AG

      Calcitonin, Renal osteodystrophy, Uremia

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Synthetic salmon calcitonin (100 MRC units/day)was administered to three patients with chronic renal insufficiency supported by maintenance hemodialysis; these patients had also developed secondary hyperparathyroidism.The diagnosis of hyperparathyroidism was based on bone pain, X-ray changesindicating subperiosteal bone reabsorption, increased levels of serum alkaline phosphatase, accelerated radiocalcium turnover, increased resorption on bone biopsy and increased levels of bone cell collagenase activity. No improvement was noted in any of the measured parameters after 4–11 weeks of calcitonin therapy. A further increase in serum alkaline phosphatase occurred in one patient and bone cell collagenase activity increased further in all three patients. These data suggest that calcitonin may exaggerate the secondary hyperparathyroidism of chronic renal failure and, therefore, is not therapeutically useful.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          1973
          1973
          28 November 2008
          : 11
          : 5
          : 287-293
          Affiliations
          Department of Medicine and USPHS Clinical Research Center, State University -Kings County Hospital Center, Downstate Medical Center, Brooklyn, N.Y.
          Article
          180236 Nephron 1973;11:287–293
          10.1159/000180236
          4753519
          © 1973 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 7
          Categories
          Paper

          Cardiovascular Medicine, Nephrology

          Uremia, Renal osteodystrophy, Calcitonin

          Comments

          Comment on this article